DEF: Gabelli Healthcare & WellnessRx Trust Sets 2026 Annual Meeting

The Gabelli Healthcare & WellnessRx Trust announced its 2026 Annual Meeting of Shareholders to elect four trustees and review corporate governance matters.

Summary

• The Gabelli Healthcare & WellnessRx Trust will hold its Annual Meeting of Shareholders on May 11, 2026, at 9:30 a.m. ET, to elect four Trustees.
• Shareholders will vote to elect Mario J. Gabelli, Agnes Mullady, and Anthonie C. van Ekris by common and preferred shareholders voting as a single class, and Vincent D. Enright by preferred shareholders voting as a separate class, each for a three-year term expiring at the 2029 Annual Meeting.
• As of the March 12, 2026 record date, the Fund had 14,771,703 Common Shares, 3,985,014 Series E Preferred Shares, and 3,087,000 Series G Preferred Shares outstanding.
• Key beneficial owners include Saba Capital Management, L.P. (14.3% Common Shares), SIT Investment Associates Inc. (7.0% Common Shares), GAMCO Investors, Inc. and affiliates (77.8% Preferred Shares), and Kenneth Edlow (9.3% Preferred Shares).
• PricewaterhouseCoopers, the Fund's independent registered public accounting firm, billed $37,077 for audit services and $4,315 for tax services for the fiscal year ended December 31, 2025.
• The Delaware Statutory Trust Act (DSTA) Control Share Statute, which can limit voting rights for large acquisitions, became applicable to the Fund on August 1, 2022, with certain preferred share acquisitions directly from the Fund or its agents being exempted by the Board.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine corporate governance filing. The detailed disclosure of board structure and oversight is positive, but the late Section 16(a) filings and the potential implications of the DSTA Control Share Statute introduce minor concerns.

Positives

• The Board of Trustees maintains a strong independent majority, with seven out of nine Trustees classified as Independent Trustees, enhancing oversight and governance.
• The Audit Committee, composed entirely of Independent Trustees, actively oversees financial reporting, internal controls, and compliance, and includes a designated financial expert (Vincent D. Enright).
• All audit, audit-related, and tax services provided by PricewaterhouseCoopers for fiscal years 2024 and 2025 were pre-approved by the Audit Committee, demonstrating robust financial oversight.
• The Fund has established clear and accessible procedures for shareholder communication with the Board, including mail and electronic options.

Negatives

• Two Trustees, Mario J. Gabelli and Anthonie C. van Ekris, each filed one late Form 4 report under Section 16(a) during the fiscal year ended December 31, 2025, indicating a lapse in regulatory compliance.
• The DSTA Control Share Statute, which became applicable to the Fund, could potentially discourage third parties from seeking control, which may reduce market demand for the Fund's common shares and increase the likelihood of trading at a discount to net asset value.
• The Board has not exempted any acquisitions from the DSTA Control Share Statute other than preferred shares acquired directly from the Fund or its agents, potentially limiting future strategic flexibility or shareholder activism.

Risks

• Control Share Acquisitions: The DSTA Control Share Statute could deprive shareholders of an opportunity to sell their shares at a premium by discouraging third parties from seeking control, potentially reducing market demand for common shares and increasing the likelihood of trading at a discount to net asset value.
• Regulatory Compliance: Lapses in Section 16(a) reporting by two Trustees indicate a potential risk in regulatory compliance, although the filing states the Fund believes such persons complied with all applicable filing requirements with the exception of these late filings.
• Shareholder Influence: The DSTA Control Share Statute's provisions regarding voting rights for control shares could be seen as limiting the influence of large shareholders on corporate decisions.
• Market Liquidity and Valuation: The DSTA Control Share Statute may reduce market demand for the Fund's common shares, potentially increasing the discount to net asset value.

Future Outlook

The filing primarily focuses on corporate governance and the upcoming election of trustees, providing no specific forward-looking financial guidance or strategic outlook for the Fund's investment performance or business operations beyond the election process.

Management Comments

• "YOUR VOTE IS IMPORTANT REGARDLESS OF THE SIZE OF YOUR HOLDINGS IN THE FUND. WE ENCOURAGE YOU TO VOTE YOUR PROXY IN ADVANCE OF THE MEETING, EVEN IF YOU PLAN TO ATTEND THE MEETING."
• "The Board believes that each Trustee's experience, qualifications, attributes or skills on an individual basis and in combination with those of other Trustees lead to the conclusion that each Trustee should serve in such capacity."
• "The Board has determined that its leadership structure is appropriate for the Fund because it enables the Board to exercise informed and independent judgment over matters under its purview, allocates responsibility among committees in a manner that fosters effective oversight, and allows the Board to devote appropriate resources to specific issues in a flexible manner as they arise."
• "The Fund should not be viewed as a vehicle for trading purposes. It is designed primarily for risk-tolerant long-term investors."

Industry Context

StockSavvy.ai notes that proxy statements like this are standard annual disclosures for closed-end funds, focusing on board elections and governance. The detailed breakdown of trustee independence and committee structures aligns with best practices for investor transparency in the asset management industry. The mention of the DSTA Control Share Statute highlights a specific regulatory environment for Delaware statutory trusts, which can differentiate them from other fund structures in terms of potential takeover defenses and shareholder activism.

Comparison to Industry Standards

• The Fund's board composition, with seven out of nine independent trustees, exceeds the typical independence requirements for investment companies, which often mandate a majority of independent directors.
• The Audit Committee's structure, with a designated financial expert and all independent members, aligns with or surpasses the standards set by major exchanges and the SEC for public companies.
• The compensation structure for independent trustees, involving an annual retainer and per-meeting fees, is a common practice in the closed-end fund industry, though the specific amounts would require comparison to peer funds to assess competitiveness.
• The application of the DSTA Control Share Statute is a specific characteristic of Delaware statutory trusts and is not universally applicable across all closed-end funds, which may be organized under different state laws or corporate structures.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• GAMCO Investors, Inc. and affiliates beneficially own 77.8% of the Fund's Preferred Shares, and Mario J. Gabelli, a Trustee and Chief Investment Officer, has significant direct and indirect interests in these entities.
• Dr. Robert C. Kolodny, an Independent Trustee, is the managing general partner of private investment partnerships (KBS Partnership and KBS III Investment Partnership) for which GAMCO Asset Management Inc. (an affiliate of the Fund's Adviser) serves as an investment adviser, receiving advisory fees of $32,158 for KBS and $64,336 for KBS III in 2025.
• Ms. Calgary Avansino, an Independent Trustee, is the daughter of Raymond C. Avansino, Jr., a Director of GAMCO Investors, Inc., the parent company of the Fund's Adviser.
• Ms. Leslie F. Foley, an Independent Trustee, is the daughter of Frank J. Fahrenkopf, Jr., who serves as a director of other funds in the Gabelli Fund Complex.
• Mr. Anthonie C. van Ekris, an Independent Trustee, serves as an independent director of Gabelli International Ltd., Gabelli Fund LDC, GAMA Capital Opportunities Master Ltd., and GAMCO International SICAV, which may be deemed controlled by Mario J. Gabelli and/or affiliates.
• Mr. Salvatore J. Zizza, an Independent Trustee, serves as an independent director of Gabelli International Ltd., which may be deemed controlled by Mario J. Gabelli and/or affiliates.
• James P. Conn, an Independent Trustee, holds warrants in PMV Consumer Acquisitions Corp. valued at $4 as of December 31, 2025.
• Salvatore J. Zizza, an Independent Trustee, holds Limited Partner Interests in Gabelli Associates Fund valued at $3,027,660 and Gabelli Performance Partnership L.P. valued at $422,118 as of December 31, 2025.

Stakeholder Impact

• Shareholders: The election of trustees directly impacts the governance and oversight of the Fund. The DSTA Control Share Statute could affect the ability of large shareholders to influence the Fund and potentially impact share price.
• Management/Trustees: The re-election process confirms their roles and responsibilities, with compensation details disclosed for the fiscal year ended December 31, 2025.
• Adviser (Gabelli Funds, LLC): The continued composition of the Board, particularly the interested trustees, maintains the existing relationship with the adviser and its affiliates.
• Auditor (PricewaterhouseCoopers): Re-appointment for FY2026 ensures continuity of audit services and ongoing oversight by the Audit Committee.

Next Steps

• Shareholders are encouraged to vote on the election of four Trustees at the Annual Meeting on May 11, 2026.
• The Fund will inform shareholders of the voting results in its Semiannual Report for the six months ended June 30, 2026.
• Shareholders intending to submit proposals for inclusion in the Fund's 2027 proxy statement must do so by December 2, 2026.
• Shareholders wishing to make other nominations or proposals for the 2027 Annual Meeting must provide notice between December 2, 2026, and January 1, 2027 (subject to meeting date adjustments).

Key Dates

Recommendation

This filing is a routine proxy statement primarily focused on the annual election of trustees and corporate governance matters. It does not contain new financial performance data, strategic shifts, or other information that would fundamentally alter the investment thesis for The Gabelli Healthcare & WellnessRx Trust. While there are minor compliance issues noted (late Section 16(a) filings) and the DSTA Control Share Statute introduces a potential long-term governance dynamic, these are not immediate catalysts for a 'buy' or 'sell' recommendation. The strong independent board majority and robust committee structures are positive for governance, supporting a 'hold' for existing investors.

Keywords

Gabelli Healthcare & WellnessRx Trust, Proxy Statement, DEF 14A, Trustee Election, Corporate Governance, Shareholder Meeting, Closed-End Fund, SEC Filing, DSTA Control Share Statute, Preferred Shares, Common Shares, Audit Committee, Nominating Committee, PricewaterhouseCoopers, GAMCO Investors